Edition:
United Kingdom

People: Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

4.90EUR
13 Sep 2019
Change (% chg)

€-0.05 (-1.01%)
Prev Close
€4.95
Open
€4.95
Day's High
€4.95
Day's Low
€4.90
Volume
8,539
Avg. Vol
24,597
52-wk High
€9.13
52-wk Low
€4.52

Scheer, Alexander 

Dr. Alexander Scheer, Ph.D., has been Chief Scientific Officer of the Company since October 27, 2016. Dr. Scheer has over 15 years of experience in R&D and the life science industry. Prior to joining ERYTECH, he served as the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research, and also served as a Deputy Head of Research at Pierre Fabre. Prior to joining Pierre Fabre, Dr. Scheer served as a Director, Global Research Informatics & Knowledge Management R&D and Project Leader, Neglected Diseases at Merck Serono in Switzerland where, among other responsibilities, he led Merck's program to develop drugs for neglected diseases in collaboration with the World Health Organization (WHO). He also served as Head of Molecular Screening and Cellular Pharmacology Department, Group Leader of Biochemical Pharmacology and Research Scientist at Serono. Dr. Scheer holds a B.Sc in Natural Sciences and M.Sc. in Chemistry, both from the University of Gottingen, and a Ph.D. in Chemistry and Biochemistry from the German Cancer Research Center.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --